Exploring an advanced four-peptide co-lyophilized formulation designed for multi-pathway recovery and anti-inflammatory research.
KLOW 80mg is an advanced co-lyophilized multi-peptide blend combining four research compounds into a single 80mg formulation: GHK-CU (50mg), BPC-157 (10mg), TB-500 (10mg), and KPV (10mg). The blend builds on the established GLOW formula by introducing KPV, an alpha-MSH fragment tripeptide composed of the amino acid sequence Lys-Pro-Val. This addition brings an anti-inflammatory research pathway into an already versatile recovery-focused formulation, making KLOW one of the most comprehensive multi-peptide blends available for preclinical investigation.
By co-lyophilizing all four peptides into a single vial, the KLOW blend ensures consistent ratios across every reconstitution, eliminating the variability that arises when researchers manually combine individual peptides. The formulation is intended for laboratory use in studies examining tissue remodeling, inflammatory modulation, wound healing, and extracellular matrix dynamics.
Each component of the KLOW blend carries a distinct body of preclinical research. GHK-CU (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper chelate first identified in human plasma. Since its discovery, extensive in vitro and in vivo studies have examined its role in collagen synthesis stimulation, extracellular matrix remodeling, and antioxidant enzyme regulation. At 50mg, GHK-CU serves as the dominant component in this blend, reflecting its central role in matrix and tissue architecture research.
BPC-157 and TB-500 are two of the most widely studied peptides in recovery science. BPC-157, a pentadecapeptide originally derived from human gastric juice sequences, has been investigated in rodent models for tendon healing, mucosal protection, and vascular repair. TB-500, a fragment of Thymosin Beta-4, has been studied for its involvement in actin regulation, cell migration, and angiogenesis. Together, these two peptides offer complementary mechanisms that have made their combination a standard in tissue repair research.
KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). Research has shown that KPV retains the anti-inflammatory properties of the parent hormone without its melanogenic effects. Preclinical studies have investigated KPV in models of intestinal inflammation, skin wound healing, and immune modulation, with findings suggesting it may inhibit pro-inflammatory cytokine production and NF-kB activation pathways. Its inclusion in the KLOW blend adds a dedicated anti-inflammatory dimension to the formulation.
GHK-CU has a molecular weight of approximately 403 Da and consists of three amino acids (Gly-His-Lys) complexed with a copper(II) ion. This copper binding is essential to its biological activity, as the metal ion participates in redox signaling and enzyme activation. BPC-157 is a 15-amino-acid peptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) with a molecular weight of approximately 1,419 Da, notable for its stability in acidic conditions. TB-500 is derived from the 43-amino-acid Thymosin Beta-4 protein with a molecular weight of approximately 4,921 Da, featuring an actin-binding domain critical to its cell migration activity.
KPV is the smallest component in the blend, consisting of just three amino acids (Lys-Pro-Val) with a molecular weight of approximately 342 Da. Despite its small size, KPV demonstrates significant biological activity in inflammatory pathways. The co-lyophilized format preserves the structural integrity of all four peptides through the freeze-drying process, yielding a total formulation weight of 80mg per vial with precisely controlled ratios.
The KLOW 80mg blend supports a wide range of preclinical research applications. In advanced recovery studies, researchers use the blend to investigate how multiple tissue repair mechanisms interact when activated simultaneously. The combination of BPC-157 and TB-500 addresses tendon, ligament, and soft tissue healing pathways, while GHK-CU contributes collagen synthesis and matrix remodeling activity.
Anti-inflammatory research benefits from the inclusion of KPV, allowing investigators to study how inflammatory modulation interacts with tissue repair processes. This is particularly relevant in wound healing models where inflammation and regeneration occur in overlapping phases. Collagen and extracellular matrix studies leverage the high concentration of GHK-CU to examine how copper peptide signaling influences fibroblast behavior, decorin expression, and matrix metalloproteinase regulation.
Additional applications include skin remodeling investigations, vascular research examining angiogenesis alongside anti-inflammatory activity, and dose-response studies where the fixed-ratio format ensures experimental consistency across treatment groups. The four-peptide design makes KLOW especially suited for multi-target research paradigms that seek to model the complexity of biological repair processes.
The lyophilized KLOW 80mg blend should be stored at -20°C for long-term preservation. Unopened vials maintained at this temperature retain stability for up to 24 months. Once reconstituted with bacteriostatic water or sterile saline, the solution should be refrigerated at 2-8°C and used within 30 days. Repeated freeze-thaw cycles should be avoided, as they can compromise the structural integrity of the peptide components, particularly the copper chelation of GHK-CU. Handle with appropriate laboratory gloves and employ sterile technique during reconstitution to prevent contamination.
This product is sold exclusively for laboratory and scientific research purposes. It is not intended for human or veterinary use, diagnostic purposes, or therapeutic applications. All research must comply with applicable laws and institutional guidelines. By purchasing, you confirm you are a qualified researcher. Please review our full legal disclaimer.